4.6 Article

Access to the Spleen Microenvironment through Lymph Shows Local Cytokine Production, Increased Cell Flux, and Altered Signaling of Immune Cells during Lipopolysaccharide-Induced Acute Inflammation

期刊

JOURNAL OF IMMUNOLOGY
卷 184, 期 8, 页码 4547-4556

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0902049

关键词

-

资金

  1. Western Norway Regional Health Authority
  2. Norwegian Cancer Society
  3. Research Council of Norway

向作者/读者索取更多资源

The spleen is involved in fluid volume regulation, immune responses, and hematopoiesis. Yet, the composition of the fluid phase within the spleen microenviroment, the migratory routes of lymphocytes as well as the splenic response to bacterial endotoxin is incomplete. To address these issues, we isolated postnodal lymph in rats by cannulating an efferent lymphatic draining the spleen, and assessed the secretion of signaling substances during a septic response induced by LPS. Spleen lymph flow increased 8-fold after LPS exposure. The spleen exhibited a permeable microvasculature with low sieving of macromolecules that was absent after exposure to LPS. Furthermore, after LPS exposure the spleen contributed significantly to the production of pro- and anti-inflammatory cytokines, and experiments in splenectomized rats suggested it may induce a protracted inflammation because of a dominant role in IL-6 production. A significant amount of lymphocytes exited via lymphatics draining the spleen in control rats. LPS-induced inflammation resulted in increased T cell and reduced B cell subset fractions, and gave a significant increase in CD4(+) and CD8(+) subset T cell efflux and a reduced B cell efflux in spleen lymph. Exposure of leukocytes to the spleen microenvironment affected their signaling status, and by phosphorylation specific flow cytometry we could identify STAT3 and CREB as important mediators in the cellular signaling occurring during endotoxemia. We conclude that analysis of spleen lymph may unravel immune cell migration patterns and local signaling, and immune cells exit via lymph having acquired specific activation signatures after exposure to the spleen microenvironment. The Journal of Immunology, 2010, 184: 4547-4556.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Neurosciences

Na+ is shifted from the extracellular to the intracellular compartment and is not inactivated by glycosaminoglycans during high salt conditions in rats

Irene Matre Thowsen, Tine Karlsen, Elham Nikpey, Hanne Haslene-Hox, Trude Skogstrand, Gwendalyn J. Randolph, Bernd H. Zinselmeyer, Olav Tenstad, Helge Wiig

Summary: Recent studies have shown that the skin acts as a major reservoir for sodium ions by regulating the content of glycosaminoglycans and osmotic gradients. This study investigated the presence of electrolyte gradients in the skin and the storage of sodium ions from a fluid balance perspective. The results revealed a gradient of sodium ions from the epidermis to the dermis, with a higher concentration in the epidermis. This hydration-dependent concentration of sodium ions in the interstitial fluid contributes to the skin barrier and limits water loss. Additionally, intracellular storage of sodium ions in muscle and myocardium may have electromechanical consequences in salt stress.

JOURNAL OF PHYSIOLOGY-LONDON (2022)

Article Medicine, Research & Experimental

Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Aslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjorge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Gronlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Donnem, Espen Enerly, Asmund Flobak, Sverre Fluge, Bjornar Gilje, Bjorn Tore Gjertsen, Bjorn Henning Gronberg, Kari Gronas, Tormod Guren, Hanne Hamre, Ase Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Asmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Katarina NilsenPuco, Anne Hansen Ree, Tonje Boyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pal Suhrke, Oyvind Tennoe, Geir E. Tjonnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebo, Kjetil Tasken, Sigbjorn Smeland

Summary: Personalized cancer care based on tumour molecular characteristics has revolutionized treatment approaches and brought hope to many patients. The implementation of emerging technologies in molecular diagnostics, publicly funded in Norway, allows for comprehensive genomic profiling of tumours, offering more cancer patients the possibility of receiving precision cancer drugs through the national infrastructure called IMPRESS-Norway.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Letter Oncology

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein

Giulia Pianigiani, Francesca Rocchio, Sara Peruzzi, Vibeke Andresen, Barbara Bigerna, Daniele Sorcini, Michela Capurro, Bjorn Tore Gjertsen, Paolo Sportoletti, Mauro Di Ianni, Maria Paola Martelli, Lorenzo Brunetti, Brunangelo Falini

LEUKEMIA (2022)

Letter Biochemistry & Molecular Biology

A national precision cancer medicine implementation initiative for Norway

Kjetil Tasken, Hege E. G. Russnes, Eline Aas, Line Bjorge, Egil S. Blix, Espen Enerly, Gro L. Fagereng, Asmund Flobak, Bjornar Gilje, Bjorn T. Gjertsen, Tormod K. Guren, Jutta Heix, Eivind Hovig, Randi Hovland, Per E. Lonning, Leonardo A. Meza-Zepeda, Per M. Maehle, Hilde L. Nilsen, Steinar O. Thoresen, Ketil Widerberg, Sigbjorn Smeland, Aslaug Helland

NATURE MEDICINE (2022)

Correction Medicine, Research & Experimental

Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (vol 20, 225, 2022)

Aslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjorge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Gronlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Donnem, Espen Enerly, Asmund Flobak, Sverre Fluge, Bjornar Gilje, Bjorn Tore Gjertsen, Bjorn Henning Gronberg, Kari Gronas, Tormod Guren, Hanne Hamre, Ase Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Asmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Nilsen, Katarina Puco, Anne Hansen Ree, Tonje Boyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pal Suhrke, Oyvind Tennoe, Geir E. Tjonnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebo, Kjetil Tasken, Sigbjorn Smeland

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Article Peripheral Vascular Disease

Genetic Engineering of Lymphangiogenesis in Skin Does Not Affect Blood Pressure in Mouse Models of Salt-Sensitive Hypertension

Irene Matre Thowsen, Tore Reikvam, Trude Skogstrand, Anne-Maj Samuelsson, Dominik N. Muller, Olav Tenstad, Kari Alitalo, Tine Karlsen, Helge Wiig

Summary: Our results suggest that dermal lymphatic vessels are not involved in salt storage or blood pressure regulation in these mouse models of salt-sensitive hypertension.

HYPERTENSION (2022)

Article Oncology

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Jesse M. Tettero, Waleed K. W. Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Catharina H. M. J. van Elssen, Thomas Fischer, Bjorn T. Gjertsen, Gwendolyn N. Y. van Gorkom, Patrycja Gradowska, Marjolein J. E. Greuter, Laimonas Griskevicius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Bob Loewenberg, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Jacqueline Cloos

Summary: Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has significant prognostic value in acute myeloid leukemia (AML). The MRD results after cycle 1 are highly concordant with MRD status after cycle 2. Using MRD-MFC to guide consolidation treatment can safely reduce the number of allogeneic donor searches and decrease costs.

FRONTIERS IN ONCOLOGY (2022)

Article Hematology

Isolation of lymph shows dysregulation of STAT3 and CREB pathways in the spleen and liver during leukemia development in a rat model

Eli Sihn Samdal Steinskog, Kenneth Finne, Marianne Enger, Lars Helgeland, Per Ole Iversen, Emmet McCormack, Helge Wiig, Olav Tenstad

Summary: This study examined the response in the interstitial fluid phase of the spleen and liver during the development of acute myeloid leukemia (AML). The results showed increased STAT3 and CREB signaling in the spleen and depressed signaling in the liver in AML. Proteins related to these pathways were also differently expressed in lymph and plasma in AML compared with the control group.

MICROCIRCULATION (2023)

Article Multidisciplinary Sciences

Early response evaluation by single cell signaling profiling in acute myeloid leukemia

Benedicte Sjo Tislevoll, Monica Hellesoy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Duran, Laure Piechaczyk, Dagim Shiferaw Tadele, Jorn Skavland, Baliakas Panagiotis, Randi Hovland, Vibeke Andresen, Ole Morten Seternes, Tor Henrik Anderson Tvedt, Nima Aghaeepour, Sonia Gavasso, Kimmo Porkka, Inge Jonassen, Yngvar Floisand, Jorrit Enserink, Nello Blaser, Bjorn Tore Gjertsen

Summary: In this study, the initial signaling response to standard induction chemotherapy in 32 acute myeloid leukemia (AML) patients was investigated using 36-dimensional mass cytometry. The reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy was found to be a significant predictor of patient 5-year overall survival in this cohort. This study demonstrates the value of mass cytometry in early response evaluation in AML and highlights the potential of functional signaling analyses in precision oncology diagnostics.

NATURE COMMUNICATIONS (2023)

Article Hematology

AML in the elderly-A global view

Peter Hokland, Isolda I. Fernandez, Sylvie D. Freeman, Bjorn T. Gjertsen, Jie Jin, Vidh Murthy, Masamitsu Yanada, Arnold Ganser

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Editorial Material Hematology

How to discover the exceptional venetoclax responders in AML/MDS?

Bjorn Tore Gjertsen

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy

Yngvar Floisand, Mats Remberger, Iris Bigalke, Dag Josefsen, Helen Valerhaugen, Else Marit Inderberg, Richard W. Olaussen, Bjorn Tore Gjertsen, Rene Goedkoop, Christiane Geiger, Petra U. Prinz, Frauke M. Schnorfeil, Kai Pinkernell, Dolores J. Schendel, Gunnar Kvalheim

Summary: For relapsing AML patients not suitable for allo-HSCT, oral azacytidine can be used as maintenance treatment in first remission, but it has substantial side effects and less toxic alternatives should be explored. In this study, autologous RNA-loaded mature dendritic cell vaccine FDC101 was used as maintenance therapy in CR1 AML patients, and the results showed good tolerability and high long-term survival.

LEUKEMIA (2023)

Article Oncology

The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?

Brunangelo Falini, Bjorn T. Gjertsen, Vibeke Andresen

LEUKEMIA (2023)

Meeting Abstract Oncology

Key learnings from building: A precision cancer medicine implementation initiative for Norway

K. Tasken, H. G. Russnes, E. Aas, L. Bjorge, E. S. Blix, E. Enerly, L. Fagereng, A. Flobak, B. Gilje, B. T. Gjertsen, T. K. K. Guren, J. Heix, E. Hovig, R. Hovland, P. E. Lonning, P. M. Maehle, H. L. Nilsen, S. Thoresen, S. Smeland, A. Helland

ANNALS OF ONCOLOGY (2022)

Meeting Abstract Oncology

The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway

A. Helland, K. Tasken, H. E. G. Russnes, L. Fagereng, E. S. Blix, S. Brabrand, T. Donnem, A. Flobak, B. T. Gjertsen, A. Haug, R. Hovland, G. Inpred, P. E. Lonning, P. Niehusmann, K. Puco, E. S. Samdal, S. Smeland

ANNALS OF ONCOLOGY (2022)

暂无数据